• Journal of Digestive Cancer Research
• /
• 제11권2호
• /
• pp.99-103
• /
• 2023

Malignant tumors located near the papilla of the duodenum can cause concomitant biliary and duodenal obstruction, which reduces the quality of life and increases the morbidity and mortality. Apart from traditional surgical treatment methods, various treatment methods such as endoscopic treatment and radiological interventions are used for the treatment. This study aimed to explore treatment methods according to the situation of patients with malignant biliary obstruction combined with duodenal obstruction.

• Korean Journal of Radiology
• /
• 제22권5호
• /
• pp.742-750
• /
• 2021

Objective: To assess the safety and clinical efficacy of percutaneous transhepatic enteral stent placement for recurrent malignant obstruction in patients with surgically altered bowel anatomy. Materials and Methods: Between July 2009 and May 2019, 36 patients (27 men and 9 women; mean age, 62.7 ± 12.0 years) underwent percutaneous transhepatic stent placement for recurrent malignant bowel obstruction after surgery. In all patients, conventional endoscopic peroral stent placement failed due to altered bowel anatomy. The stent was placed with a transhepatic approach for an afferent loop obstruction (n = 27) with a combined transhepatic and peroral approach for simultaneous stent placement in afferent and efferent loop obstruction (n = 9). Technical and clinical success, complications, stent patency, and patient survival were retrospectively evaluated. Results: The stent placement was technically successful in all patients. Clinical success was achieved in 30 patients (83.3%). Three patients required re-intervention (balloon dilatation [n = 1] and additional stent placement [n = 2] for insufficient stent expansion). Major complications included transhepatic access-related perihepatic biloma (n = 2), hepatic artery bleeding (n = 2), bowel perforation (n = 1), and sepsis (n = 1). The 3- and 12-months stent patency and patient survival rates were 91.2%, 66.5% and 78.9%, 47.9%, respectively. Conclusion: Percutaneous enteral stent placement using transhepatic access for recurrent malignant obstruction in patients with surgically altered bowel anatomy is safe and clinically efficacious. Transhepatic access is a good alternative route for afferent loop obstruction and can be combined with a peroral approach for simultaneous afferent and efferent loop obstruction.

• Journal of Digestive Cancer Reports
• /
• 제9권2호
• /
• pp.43-49
• /
• 2021

Background/Aims: Colonic stenting as a bridge to elective surgery is an alternative for emergency surgery in patients with acute malignant colonic obstruction. However, since its benefits are uncertain, we aimed to establish whether it has better clinical outcomes. Methods: The patients with acute malignant left-sided colon obstruction enrolled from January 2009 to December 2018 in National Health Insurance Service Ilsan Hospital. The patients were enrolled to undergo colonic stenting as a bridge to elective surgery or emergency surgery. The following oncological outcomes were assessed: incidence of complete remission, disease progression, local recurrence, and systemic recurrence. Results: Out of 40 patients, 33 received self-expanding metallic stent (SEMS) as a bridge-to-surgery, and 7 underwent emergency surgery. More stoma was made in case of emergency surgery with statistical significance (p < 0.001). There were no significant differences in complete remission rate in curable left-sided malignant colonic obstruction between SEMS as a bridge-to-surgery and emergency surgery. Complete remission was achieved for 3 patients (42.9%) in the non-stent group and 27 patients (81.8%) in the stent group. There was no statistically significant difference in oncologic outcomes between the two groups (p = 0.069). According to multi-variate analysis, advanced TNM stage, Adjuvant chemotherapy, and SEMS bridge-to-surgery were significantly associated with disease-free survival. Disease-free survival rate differed significantly between the two groups (p = 0.024). Conclusions: SEMS as a bridge-to-surgery might be an effective strategy and reduce stoma formation in acute malignant left-sided colon obstruction.

• Clinical Endoscopy
• /
• 제56권2호
• /
• pp.135-142
• /
• 2023

Endoscopic biliary drainage strategies for managing unresectable malignant hilar biliary obstruction differ in terms of stent type, drainage area, and deployment method. However, the optimal endoscopic drainage strategy remains unclear. Uncovered self-expandable metal stents (SEMS) are the preferred type because of their higher functional success rate, longer time to recurrent biliary obstruction (RBO), and fewer cases of reintervention than plastic stents (PS). Other PS subtypes and covered SEMS, which feature a longer time to RBO than PS, can be removed during reintervention for RBO. Bilateral SEMS placement is associated with a longer time to RBO and a longer survival time than unilateral SEMS placement. Unilateral drainage is acceptable if a drainage volume of greater than 50% of the total liver volume can be achieved. In terms of deployment method, no differences were observed in clinical outcomes between side-by-side (SBS) and stent-in-stent deployment. Simultaneous SBS boasts a shorter procedure time and higher technical success rate than sequential SBS. This review of previous studies aimed to clarify the optimal endoscopic biliary drainage strategy for unresectable malignant hilar biliary obstruction.

• Journal of Hospice and Palliative Care
• /
• 제8권2호
• /
• pp.200-208
• /
• 2005

목적: 악성 위장관 폐색 환자에서 완화적 시술이나 수술은 폐색의 다양한 증상을 조절할 뿐만 아니라 삶의 질을 향상시킨다. 본 연구는 완화적인 시술을 받았던 악성 위장관 폐색 말기암 환자의 임상적 특징과 예후인자를 알아보고자 하였다. 방법: 2002년 5월부터 2005년 5월까지 본원에서 악성 위장관 폐색으로 진단받아 완화적인 시술을 받았던 48명의 말기암 환자를 대상으로 후향적으로 조사하였다. 완화적인 암절제 환자는 제외하였다. 임상적 특성과 시술내용을 조사하였고 예후인자는 log-rank test를 이용한 단변량 분석을 하고 통계적으로 의미 있는 인자는 Cox's proportional hazard model을 사용하여 다변량 분석을 하였다. 결과: 연령의 중앙값은 65세이고 남자가 25명(52%), 여자가 23명(48%)이었다. 가장 많은 암은 대장직장암으로 26명(55%)이고 다음으로 10명(21%)의 위암이었다. 치료를 전혀 받지 않았던 환자는 25명(58%)이었고 20명(42%)은 치료를 받았으며 이 중 18명은 항암 치료를 받은 과거력이 있었다. 가장 흔한 증상은 통증으로 15명(31%)이었다. 활동도 1점 혹은 2점이 23명(48%), 3점 혹은 4점이 25명(52%)이었다. 가장 많은 완화적인 시술은 대장루술로 19명이 받았다. 완화적 시술로 인한 사망은 없었다. 단변량과 다변량 분석에 의해서 전체 생존기간과 무증상 생존기간에 대하여 활동도 만이 의미있는 독립 예후인자였다. 전체 중간 생존기간은 150일이었으며 무증상 중간 생존기간은 90일이었다. 결론: 완화적 시술을 받은 악성 위장관 폐색 환자의 전체 중간 생존기간과 무증상 중간 생존기간에 대하여 활동도만이 유일한 독립 예후인자였다.

• Journal of Hospice and Palliative Care
• /
• 제7권2호
• /
• pp.214-220
• /
• 2004

목적: 말기암 환자의 장 폐색은 예후가 비교적 나쁘다. 의사들도 삶의 질 측면에서 완화적인 시술이나 수술을 고려하고 있으나 결정하기가 어려운 경우가 있다. 본 연구는 말기암 환자의 장 폐색 진단 후 임상적 특징, 완화적 시술이나 수술을 받았던 환자에서 생존 기간과 예후 인자를 조사하여 보고자 하였다. 방법: 2002년 5월부터 2004년 5월까지 본원을 방문한 말기암 환자로 장 폐색 진단을 받았던 40명 환자의 의무기록을 후향적으로 조사하였다. 결과: 남자가 21명(53%), 여자가 19명(47%)였고 나이의 중간값은 $64.1{\pm}1.58$세였다. 장 폐색의 가장 많은 원인은 대장직장암이 18명(45%)이였으며 위암 11명(28%), 췌장암 4명(10%), 기타 7명(19%) 순이였다. 장 폐색 진단 시 가장 많은 전이는 복막전이가 14명(35%) 가장 많았고 다음이 간 전이가 13명(33%)였다. 폐색 시 증상은 구토가 15명(38%)로 가장 많았고 복부통증 10명(25%), 변비 6명(15%), 복부 팽만 5명(13%) 이였다. 일상수행능력(ECOG)은 3점이 20명(50%0, 2점 16명(40%), 4점(10%)였다. 완화적 시술이나 수술을 받았던 군이 30명이였고 받지 않았던 군이 10명이였다. 완화적 시술이나 수술을 받았던 군에서 치료를 받았던 시점에서 중간생존기간은 142일로 받지 않았던 군의 장 폐색 진단시부터 중간생존기간 30일에 비하여 유의하게 중간 생존기간이 길었다. 예후 인자로는 생활수행능력상태 2점과 하부 장 폐색과 대장암에 의해서 폐색이 있는 경우에 유의하게 생존기간이 길었다. 결론: 말기암 환자의 장 폐색은 적응증이 될 경우에 적극적인 완화적 시술이나 수술을 고려하는 것이 좋을 것으로 생각된다.

• Journal of Gastric Cancer
• /
• 제8권3호
• /
• pp.148-153
• /
• 2008

목적: 위암의 재발로 발생한 악성 장폐쇄증은 치료의 효과와 생존율을 향상시키기 위하여 적합하게 치료되어야 한다. 본 연구에서는 위암으로 수술 후 재발되어 악성 장폐쇄증이 발생한 경우 수술 방법에 따른 치료 효과와 생존율의 차이를 알아보았다. 대상 및 방법: 1998년 1월부터 2008년 3월까지 위암의 재발로 악성 장폐쇄증이 발생하여 수술적 치료를 받은 환자들의 의무 기록을 후향적으로 분석하였다. 수술 방법은 절제술, 장루술, 우회술로 나누었고 치료의 성공은 유동식 이상의 경구 섭취가 가능한 것으로 보았다. 결과: 42명의 환자에 대해 46회의 수술이 시행되었으며 절제술이 12회, 장루술이 24회, 위회술이 10회이었다. 입원기간과 유동식 이상의 경구 섭취까지의 기간은 장루술이 가장 짧았다. 수술 후 합병증은 10예(21.7%)에서 있었고 수술 후 30일 이내에 사망한 경우는 4예(8.7%)이었다. 수술 방법에 따른 생존율의 차이는 없었다. 결론: 위암의 재발로 발생한 악성 장폐쇄증의 수술적 치료로 장루술은 입원일과 경구 섭취까지의 기간이 다른 수술법에 비해 짧기 때문에 일부 환자들에서 좋은 선택이 될 수 있다. 수술 방법에 따른 생존율의 차이는 없었으며 이는 악성 장폐쇄증의 경우 근치적 수술이 어려운 경우가 대부분이기 때문으로 생각된다.

• Clinical Endoscopy
• /
• 제56권2호
• /
• pp.155-163
• /
• 2023

Malignant hilar biliary obstruction (MHO), an aggressive perihilar biliary obstruction caused by cholangiocarcinoma, gallbladder cancer, or other metastatic malignancies, has a poor prognosis. Surgical resection is the only curative treatment for biliary malignancies. However, the majority of patients with MHO cannot undergo surgery on presentation because of an advanced inoperable state or a poor performance state due to old age or comorbid diseases. Therefore, palliative biliary drainage is mandatory to improve symptomatic jaundice and the quality of life. Among the drainage methods, endoscopic biliary drainage is the current standard for palliation of unresectable advanced MHO. In addition, combined with endoscopic drainage, additional local ablation therapies, such as photodynamic therapy or radiofrequency ablation (RFA), have been introduced to prolong stent patency and survival. Currently, RFA is commonly used as palliative therapy, even for advanced MHO. This literature review summarizes recent studies on RFA for advanced MHO.

• Journal of Digestive Cancer Research
• /
• 제12권1호
• /
• pp.15-22
• /
• 2024

Malignant colorectal obstructions urgently require decompression therapy to prevent the severe risks of intestinal ischemia and bowel perforation. In managing malignant colonic strictures endoscopically, the use of self-expandable metal stents (SEMS) is the predominant approach. Colonic SEMs are primarily used in preoperative decompression therapy before curative surgery and palliative treatment in patients with advanced disease stages. Furthermore, the stenting process, which requires rigorous clinical supervision, can lead to complications. This review endeavors to concisely review the clinical considerations associated with the SEMS procedure, with a focus on its indications, technical aspects, and potential complications that may arise during the procedure.

• Clinical Endoscopy
• /
• 제57권3호
• /
• pp.375-383
• /
• 2024

Background/Aims: Endoscopic self-expandable metal stent (SEMS) placement is currently the standard technique for treating unresectable malignant distal biliary obstructions (MDBO). Therefore, covered SEMS with longer stent patency and fewer migrations are required. This study aimed to assess the clinical performance of a novel, fully covered SEMS for unresectable MDBO. Methods: This was a multicenter single-arm prospective study. The primary outcome was a non-obstruction rate at 6 months. The secondary outcomes were overall survival (OS), recurrent biliary obstruction (RBO), time to RBO (TRBO), technical and clinical success, and adverse events. Results: A total of 73 patients were enrolled in this study. The non-obstruction rate at 6 months was 61%. The median OS and TRBO were 233 and 216 days, respectively. The technical and clinical success rates were 100% and 97%, respectively. Furthermore, the rate of occurrence of RBO and adverse events was 49% and 21%, respectively. The length of bile duct stenosis (<2.2 cm) was the only significant risk factor for stent migration. Conclusions: The non-obstruction rate of a novel fully covered SEMS for MDBO is comparable to that reported earlier but shorter than expected. Short bile duct stenosis is a significant risk factor for stent migration.